Pharmacological management of relapsed/refractory NSCLC with chemical drugs
Por:
Karachaliou, N, Sosa, AE, Barron, FB, Cao, MG, Santarpia, M and Rosell, R
Publicada:
1 ene 2017
Resumen:
Introduction: Lung cancer is the leading cause of cancer death in both genders. In the early stages the disease is asymptomatic and most patients appear with metastasis at the time of the diagnosis. The discovery of key oncogenic events mainly in lung adenocarcinoma, like EGFR mutations or ALK rearrangements has changed the treatment landscape and has improved the prognosis of lung cancer patients. Inevitably, all patients initially treated with either chemotherapy or targeted therapies develop resistance and require a second-line therapeutic approach.
Areas covered: In this review we are discussing the current treatment of relapsed or refractory lung cancer. We have thoroughly searched the literature (Pubmed) the last five years for studies or reviews published on the issue of second-line therapy in lung cancer using as key words, lung cancer, relapse, EGFR mutations, ALK rearrangements, chemotherapy and immunotherapy
Expert opinion: The prognosis of lung cancer has been radically improved. Due to the recent development of checkpoint inhibitors, this also occurs for patients whose tumor's are not driven by a genetic alteration and who, until recently, derived only minimal benefit from chemotherapy.
Filiaciones:
Karachaliou, N:
Univ Hosp Sagrat Cor, Inst Oncol Dr Rosell IOR, Barcelona, Spain
Sosa, AE:
Univ Hosp Sagrat Cor, Inst Oncol Dr Rosell IOR, Barcelona, Spain
Barron, FB:
Inst Nacl Cancerol, Dept Med Oncol, Mexico City, DF, Mexico
Cao, MG:
Quiron Dexeus Univ Inst, Inst Oncol Dr Rosell IOR, Barcelona, Spain
Santarpia, M:
Univ Messina, Dept Human Pathol G Barresi, Med Oncol Unit, Messina, Italy
:
Inst Invest Ciencies Germans Trias & Pujol, Canc Biol & Precis Med Program, Badalona, Spain
Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
|